Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations

Documenti analoghi

• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  di: Oxnard, Geoffrey R., et al.
  Pubblicazione: (2011)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  di: Zakowski, Maureen F., et al.
  Pubblicazione: (2009)
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  di: Pao, William, et al.
  Pubblicazione: (2005)
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  di: Pao, William, et al.
  Pubblicazione: (2005)
• Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
  di: Rizvi, Naiyer A., et al.
  Pubblicazione: (2011)